Objectives: This study’s main aim was to identify factors that are associated with the development of left atrial myopathy in patients without atrial fibrillation. The hypothesis states that left atrial myopathy can be detected in patients without atrial fibrillation and it is correlated to comorbidities. Materials and methods: Sixty-five consecutive patients (40 male, 57.65 ±13.6 years old) with normal sinus rhythm (SR) and without a history of atrial fibrillation (AF) underwent late gadolinium enhancement – magnetic resonance imaging (LGE-MRI) to assess for fibrosis in the left atrium (LA). Each LGE-MRI was segmented by isolation of the LA wall and quantified for the relative extent of fibrotic remodeling using the Corview software (Marrek Inc.). The comorbidities were documented and their correlation with the degree of left atrial fibrosis was investigated through the implementation of univariate and multivariate analyses. Data collection included demographic information, comorbidities and regularly taken medication. The information was collected anonymously in Excel for statistical analysis with R Version 4.3.0, focusing on variables with p-values <0.05 to identify significant comorbidities. Results: In a study of 65 patients (40 male, 57.65 ±13.6 years old) with normal sinus rhythm and no atrial fibrillation, the mean degree of left atrial (LA) fibrosis was 13.52 ± 7.7 percent, with LA volume of 76.13 ± 28.02cm3. The prevalence of LA-fibrosis varies between 2.6% and 34.7%. In the univariate analysis, age (p=0.022), mitral valve regurgitation (p=0.007), congestive heart failure (p=0.026), LA volume (p<0.001), weight (p=0.010), acetylsalicylic acid (p=0.011) and cardiomyopathy (p=0.032) were all significantly associated with the extent of left atrial fibrosis. The significance of LA volume (p<0.001) is maintained in multivariable analysis. Conclusion: This study concludes that a substantial proportion of individuals may have structural fibrotic alterations prior to the onset of atrial fibrillation, as evidenced by the high prevalence of atrial fibrosis among non-AF patients. There appears to be an association between the development of atrial cardiomyopathy and a range of cardiac and non-cardiac comorbidities, according to our research. As a result, routine monitoring for atrial fibrillation should be conducted on these patients.